Immunovant Inc [IMVT] stock is trading at $17.35, up 1.88%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMVT shares have gain 4.83% over the last week, with a monthly amount glided 7.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Hold rating on March 03, 2025, and set its price target to $20. On January 03, 2025, downgrade downgraded it’s rating to Peer Perform. Oppenheimer reiterated its recommendation of a Outperform and raised its price target to $53 on October 09, 2024. Oppenheimer started tracking with a Outperform rating for this stock on March 28, 2024, and assigned it a price target of $50. In a note dated March 13, 2024, Goldman initiated an Buy rating and provided a target price of $50 on this stock.
Immunovant Inc [IMVT] stock has fluctuated between $12.72 and $32.10 over the past year. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $17.35 at the most recent close of the market. An investor can expect a potential return of 146.86% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at -1.34% with Operating Profit Margin at -2944.34%, Pretax Profit Margin comes in at -2784.85%, and Net Profit Margin reading is -2795.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -0.84 and Total Capital is -0.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 12.32. Also, the Quick Ratio is 12.32, while the Cash Ratio stands at 11.32.
Transactions by insiders
Recent insider trading involved Geffner Michael, Chief Medical Officer, that happened on Oct 08 ’25 when 1272.0 shares were sold. Chief Technology Officer, Stout Jay S completed a deal on Oct 08 ’25 to sell 1585.0 shares. Meanwhile, Chief Technology Officer Stout Jay S sold 2805.0 shares on Jul 23 ’25.
